Expected Moves

Q3 2026 earnings evaluating cash runway from a $0.22 base. Upside targets $0.45 on clinical pipeline surprises, while base-case burn tracks toward a $0.12 fallback.

End-of-year clinical pipeline update anchoring at $0.12. Strong FDA or trial data could drive a re-rating to $0.28, but historical delays in micro-cap biotechs favor a $0.08 fallback.

Q4 2026 earnings from a $0.08 base. Non-dilutive funding bridges could spike shares to $0.18, whereas standard operating losses likely force a $0.05 fallback as dilution risks loom.

High-risk capital raise or secondary offering projected from a $0.05 base. Strategic partnerships could avert disaster for a $0.08 target, but toxic financing structures default to a $0.03 fallback.

Q1 2027 earnings release from a $0.03 base. Execution proof post-dilution aims for a $0.07 target, while continued fundamental deterioration pressures the valuation to a $0.02 fallback.

Annual shareholder meeting assessing reverse split risks from a $0.02 base. Compliance relief targets $0.05, though the high likelihood of a reverse stock split approval points to a $0.01 fallback.

Q2 2027 results evaluated from a $0.01 base. Survival and restructuring clarity targets $0.03, whereas persistent cash burn risks a terminal slide toward a $0.01 fallback.